Sarepta Therapeutics Inc
SRPT17.955USD
+0.905+5.31%
交易中 （美東）報價延遲15分鐘
1.75B總市值
虧損本益比TTM
關於 Sarepta Therapeutics Inc 公司
Sarepta Therapeutics, Inc. 是一家商業階段的生物製藥公司。該公司致力於通過發現和開發針對核糖核酸 (RNA) 的療法、基因療法和其他用於治療罕見疾病的基因治療方式來幫助患者。該公司已開發了多種用於治療杜氏肌營養不良症 (Duchenne) 的獲批產品，並正在開發用於治療一系列疾病和病症的潛在治療候選藥物，包括杜氏肌營養不良症、肢帶型肌營養不良症 (LGMD) 和其他神經肌肉和中樞神經系統 (CNS) 相關疾病。該公司已開發並商業化了四種獲批的杜氏肌營養不良症治療產品：EXONDYS 51（eteplirsen）注射液（EXONDYS 51）、VYONDYS 53（golodirsen）注射液（VYONDYS 53）、AMONDYS 45（casimersen）注射液（AMONDYS 45）和ELEVIDYS。其產品線包括約40個處於不同發現、臨牀前和臨牀開發階段的項目。
公司簡介
公司代碼SRPT
公司名稱Sarepta Therapeutics Inc
上市日期Jun 04, 1997
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
員工數量1372
證券類型Ordinary Share
年結日Jun 04
公司地址215 First Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02142
電話16172744000
網址https://www.sarepta.com/
公司代碼SRPT
上市日期Jun 04, 1997
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Ms. Cristin L. Rothfuss
Ms. Cristin L. Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
業務USD
名稱
營收
佔比
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
地區USD
名稱
營收
佔比
United States
560.81M
75.29%
Rest of World
50.71M
6.81%
業務
地區
業務USD
名稱
營收
佔比
ELEVIDYS
374.99M
50.34%
PMO Products
236.54M
31.76%
collaboration and other
133.33M
17.90%
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Global Advisors (US)
4.49%
Two Sigma Investments, LP
3.96%
其他
67.15%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Global Advisors (US)
4.49%
Two Sigma Investments, LP
3.96%
其他
67.15%
股東類型
持股股東
佔比
Investment Advisor
32.82%
Investment Advisor/Hedge Fund
20.56%
Hedge Fund
20.02%
Research Firm
5.08%
Individual Investor
4.67%
Bank and Trust
1.23%
Pension Fund
1.17%
Sovereign Wealth Fund
0.90%
Insurance Company
0.03%
其他
13.52%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
9.01M
9.17%
-59.02K
-0.65%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.90M
9.06%
-32.03K
-0.36%
Mar 31, 2025
State Street Global Advisors (US)
4.07M
4.14%
-1.39K
-0.03%
Mar 31, 2025
Barry (Richard J)
3.21M
3.27%
+32.60K
+1.02%
May 16, 2025
Wellington Management Company, LLP
2.65M
2.69%
+577.85K
+27.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.82M
1.85%
+114.57K
+6.71%
Mar 31, 2025
Erste Asset Management GmbH
1.06M
1.08%
+352.82K
+49.82%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月6日 週六
更新時間: 9月6日 週六
機構名稱
佔比
iShares Core S&P U.S. Value ETF
0%
iShares Core S&P U.S. Value ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
